Radiotherapy Devices Market

Radiotherapy Devices Market Size, Market Forecast and Outlook By FACT.MR

The Radiotherapy Devices market was valued at USD 5.35 billion in 2025, projected to reach USD 5.72 billion in 2026, and is forecast to expand to USD 11.26 billion by 2036 at a 7.0% CAGR. Accelerating global cancer incidence across aging demographics, combined with expanding radiotherapy infrastructure investment in emerging healthcare markets, drives systematic procurement of advanced radiation delivery systems. Technological transition from conventional linear accelerators toward image-guided, intensity-modulated, and stereotactic platforms creates incremental capital expenditure demand at established oncology centers undertaking equipment refresh cycles.

The absolute dollar growth of USD 5.54 billion across the forecast decade reflects both volume expansion from new facility installations and per-unit revenue growth from the shift toward advanced radiotherapy system categories. External Beam Radiotherapy Systems capturing 58.6% of product type share confirms the continued clinical preference for non-invasive external radiation delivery as the primary modality, while the 54.1% procedure share for external beam radiotherapy underscores the volume dominance of outpatient radiotherapy fractionation schedules. Cancer Treatment application capture of 42.7% of application share reflects the disease-specific concentration of device utilization in oncology departments.

As per FACT.MR's regional projections, India leads at 8.75% CAGR as the National Cancer Grid expansion program funds linear accelerator procurement for government hospital oncology centers across all major states. Germany advances at 8.05% as Deutsche Krebshilfe-funded radiotherapy center upgrades and statutory health insurance coverage for advanced radiotherapy techniques support consistent equipment investment. Brazil registers 7.35% growth as INCA's national radiotherapy network expansion deploys new linac installations across underserved regional cancer treatment centers. The United Kingdom records 6.65%, where NHS cancer plan radiotherapy service improvements fund linear accelerator fleet replacements across NHS trust oncology departments. The United States grows at 5.95% as established private oncology center capital budgets maintain steady equipment refresh and stereotactic platform upgrade cycles. Japan advances at 5.25% as the government-supported cancer control plan sustains structured radiotherapy equipment procurement funding across prefectural cancer centers.

Radiotherapy Devices Market Key Takeaways

Radiotherapy Devices Market Definition

Radiotherapy Devices encompass medical equipment systems designed to deliver controlled ionizing radiation to cancerous and benign tissue targets for therapeutic purposes. Core device categories include external beam radiotherapy systems comprising linear accelerators, proton therapy devices, and stereotactic radiosurgery platforms, and internal beam brachytherapy systems delivering radiation from implanted or applied radioactive sources. Radiotherapy software for treatment planning, dosimetry verification, and quality assurance falls within the defined market scope.

Radiotherapy Devices Market Inclusions

Market scope covers external beam radiotherapy systems, linear accelerator devices, proton therapy equipment, internal beam brachytherapy systems, and radiotherapy planning and delivery software deployed in hospitals and independent radiotherapy centers. Application coverage spans cancer treatment across prostate, breast, lung, head and neck, colorectal, gynecological, and cervical cancer indications. Regional and country-level market sizing encompasses North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa from 2026 to 2036.

Radiotherapy Devices Market Exclusions

Diagnostic radiology imaging equipment including CT scanners, PET-CT systems, and MRI devices used exclusively for treatment planning without therapeutic radiation delivery capabilities are excluded. Radiation protection equipment, dosimetry calibration instruments, and radioactive material handling infrastructure fall outside analytical boundaries. Chemotherapy drug infusion systems and immunotherapy delivery platforms without radiation delivery components are omitted. Nuclear medicine diagnostic devices and cyclotron facilities operated exclusively for isotope production are explicitly excluded.

Radiotherapy Devices Market Research Methodology

• Primary Research: Analysts conducted interviews with oncology department capital planning directors, hospital biomedical engineering managers, and national cancer program procurement officers to document radiotherapy device investment timelines.
• Desk Research: Data collection aggregated national cancer control program radiotherapy infrastructure reports, medical device regulatory authority approval databases, and health technology assessment body radiotherapy reimbursement publications.
• Market-Sizing and Forecasting: Baseline values derive from bottom-up aggregation of radiotherapy device installed base globally, applying cancer incidence growth rates and radiotherapy utilization benchmarks to project equipment demand.
• Data Validation and Update Cycle: Forecasts cross-validate against publicly reported medical device segment revenues from Varian Medical Systems, Elekta AB, and Accuray Inc. annual investor disclosures.

Summary of Radiotherapy Devices Market

• Radiotherapy Devices Market Definition
  • The Radiotherapy Devices market comprises external beam radiotherapy systems, linear accelerators, proton therapy devices, brachytherapy equipment, and treatment planning software deployed for cancer treatment and other radiotherapy applications in hospitals and independent treatment centers.
• Demand Drivers in the Market
  • Accelerating global cancer incidence rate growth across aging populations over 60 years of age creates sustained demand for radiotherapy device procurement as oncology departments expand treatment capacity.
  • Government-funded national cancer control programs in India, Brazil, and the United Kingdom designate radiotherapy equipment procurement as a priority capital investment for reducing treatment access inequality across underserved regions.
  • Technological transition toward image-guided intensity-modulated radiotherapy and stereotactic radiosurgery platforms drives capital expenditure demand beyond simple device replacement into higher-value system categories.
• Key Segments Analyzed in the FACT.MR Report
  • External Beam Radiotherapy Systems leads by Product Type with 58.6% share in 2026, reflecting the clinical preference for non-invasive external radiation delivery across the majority of solid tumor treatment protocols.
  • External Beam Radiotherapy captures 54.1% of Procedure share in 2026, as outpatient fractionated radiotherapy schedules generate high-volume device utilization across hospital and independent center facilities.
  • Cancer Treatment accounts for 42.7% of Application share in 2026, with solid tumor radiotherapy concentrating device utilization across prostate, breast, lung, and head and neck cancer treatment protocols.
• Analyst Opinion at FACT.MR

  • Shambhu Nath Jha, Principal Consultant, opines: 'Radiotherapy device procurement cycles are increasingly defined by technical specification thresholds rather than price alone. Oncology center capital committees evaluate vendors on image guidance resolution, treatment planning software integration, and adaptive radiotherapy readiness rather than linac output specifications that have converged across major platform categories. Manufacturers whose software ecosystems cannot demonstrate interoperability with hospital information systems and treatment planning platforms face disqualification from integrated oncology center procurement tenders where workflow integration criteria rank above hardware specifications in scoring matrices.'

• Strategic Implications / Executive Takeaways
  • Radiotherapy device manufacturers must obtain CE marking under EU MDR 2017/745 and FDA PMA or 510(k) clearance for advanced platform categories to qualify for participation in government cancer program procurement tenders.
  • Emerging market entry into India and Brazil requires localized service infrastructure deployment and government hospital procurement qualification to compete for national cancer network expansion contracts.
  • Software ecosystem development, including treatment planning integration, adaptive radiotherapy capability, and outcomes data analytics, serves as the primary competitive differentiator in established market renewal cycles.
• Methodology
  • Primary Research: FACT.MR interviewed oncology department capital planning directors and national cancer program procurement officers across 40 countries to validate equipment investment timelines.
  • Desk Research: Analysts aggregated national cancer control program infrastructure reports, regulatory approval databases, and health technology assessment reimbursement publications.
  • Market-Sizing and Forecasting: Bottom-up aggregation of radiotherapy device installed base with cancer incidence growth rates and radiotherapy utilization benchmarks applied to demand projections.
  • Data Validation: Cross-validation against Varian Medical Systems, Elekta AB, and Accuray Inc. annual investor disclosures for radiotherapy device segment revenues.

Revenue Analysis of Radiotherapy Devices from 2021 to 2025 Vs Market Outlook for 2026 to 2036

Improving the quality of life of cancer patients and survivors are becoming more important than the efficacy of treatments. Against the backdrop of health risks associated with prominent cancer treatment procedures such as chemotherapy, patients and oncologists are turning towards radiotherapy as the most soothing option in the treatment of cancers.

The global cancer incidence rate is expected to soar uncontrollably, particularly due to the emergence of new complications arising from exposure to toxic materials.

Demand for radiotherapy delivery systems will continue to grow in parallel with the adoption of radiotherapy procedures for cancer treatments. Reduced hospital stay, effectively control over the growth of tumorous tissues, and low exposure to undue radiation are serving as proponents of using radiotherapy devices in the oncological treatment of cancer.

Going forward, the global market for radiation therapy devices is expected to witness higher participation of top manufacturers of radiotherapy devices towards product innovation.

Latest trends in radiotherapy software, rising sales of conventional linear accelerators, and growing demand for advanced stereotactic radiotherapy units are fueling the market growth.

How are Technological Advancements in Radiotherapy Devices Fueling Market Growth?

Technology is assisting in the development of low-cost, more effective and efficient, and user-friendly solutions with radiotherapy products with improved and precise radiation dose delivery for improved tumor targeting performance.

High conformity of radiation to the target (with little exposure to normal tissue) and dose escalation with enhanced tumor control have been possible by the advancement from 2D to 3D conformal radiotherapy with real-time imaging.

Products that give these advantages are projected to have a very high growth potential in a short period of time, particularly in established markets where latest radiotherapy machines are widely adopted.

Such advanced technologies in radiotherapy software aim to improve the functionality of radiotherapy delivery systems while also broadening their scope of application. One of the primary factors driving the growth of the radiotherapy positioning devices market is increasing the acceptance of radiation therapy devices in a variety of applications and settings.

Latest innovations in radiotherapy devices, growing demand for external beam therapy (EBT), and rising sales of electron-emitting high-energy linear accelerators are projected to fuel the market growth over the forecast period.

What Barriers are Encountered by Radiotherapy Device Manufacturers?

Size of radiotherapy equipment is larger and it requires a lot of area to be installed. As a result, one of the key problems limiting the adoption of advanced radiotherapy devices in emerging and developing nations is a lack of suitable healthcare infrastructure due to limited healthcare expenditure.

The risk of radiation exposure is one of the most significant issues related with the use of advanced radiotherapy devices for cancer treatment. The high radiation doses associated with therapeutic exposures have the potential to injure not only the patients receiving treatment, but also the healthcare workers and others in the surrounding region if involuntary radiation exposure occurs.

This can cause a variety of adverse effects, including nausea, vomiting, and diarrhea. Similarly, simultaneous exposure to a significant number of radiation doses can result in radiation illness and death. These factors are restraining radiotherapy equipment market growth to some extent.

Which is the Most Profitable Regional Market for Radiotherapy Device Suppliers?

Europe is likely to be a major revenue-generating region. Revenue in the European regional market is projected to expand 1.5X by 2031.

With soaring incidence of cancers across European countries, the healthcare infrastructure in this region is expected to remain lucrative for adoption of effective cancer therapies such as radiotherapy.

Demand for radiotherapy devices and techniques is expected to gain traction in Europe owing to its advantage over other cancer therapeutic devices in terms of controlling the growth of malignant tumors. Moreover, cancer patients are likely to remain more inclined towards external beam therapy (EBT) that limit hospital stay duration.

Growing demand for 3D conformal radiotherapy devices, rising adoption of latest radiotherapy machines, and increasing sales of proton therapy devices are expected to drive market growth in Europe over the next ten years.

Growing demand for external beam radiation therapy devices in the U.K. and rising sales of linear accelerators in Australia are making a significant contribution to global market growth prospects for radiotherapy devices.

Country-wise Analysis

What is the Demand Outlook for Radiotherapy Devices in the U.S.?

The U.S. market for radiotherapy devices is expected to increase 1.7X by 2031. In the U.S, changing lifestyles of consumers and penetration of urban cultures are fueling the incidence of pancreatic cancer.

Radiotherapy devices are expected to remain of great use in the treatment of pancreatic cancer and borderline respectable cancer. Rising sales of proton therapy devices in the U.S. and presence of manufacturers of radiotherapy devices in the U.S. are fueling regional market growth.

How Lucrative is the Market for Radiotherapy Devices in China?

Improving healthcare infrastructure, large pool of people with chronic diseases, and rising sales of electronic brachytherapy products in the country are fueling market growth.

Favorable industrial regulations, low wages, and high resource availability are expected to boost sales of radiotherapy devices in China.

Category-wise Insights

Why are Linear Accelerator Devices in Such High Demand?

With continued advancements in medical technology, linear accelerator devices have emerged to become top-selling products in the global market for radiotherapy devices. Sales of linear accelerator devices are expected to increase 2.1X over the forecast period.

In external beam radiotherapy systems, the linear accelerator is the primary and most extensively utilized treatment equipment. Linear accelerator devices enhance the velocity of charged subatomic particles across a linear route using high-energy radiofrequency electromagnetic waves.

A modulator, gantry, electron gun, RF power supply, and accelerator guide are the main components of these accelerators. IMRT, IGRT, 3D conformal radiation (3D-CRT), and stereotactic technologies can all benefit from linear accelerators.

Viewed as the most-advanced radiotherapy devices, linear accelerators produce radiation and deliver it precisely in critical procedures such as intensity modulated radiation therapy and intraoperative radiation therapy.

Why is Demand for Radiotherapy Devices Highest from Hospitals?

The hospitals segment is likely to account for a majority of the market share of radiotherapy devices.

One of the primary factors leading to the growth of the radiotherapy market at hospitals is rising number of private hospitals in emerging markets, combined with the vast pool of cancer patients visiting hospitals for diagnosis and treatment.

Other significant factors supporting growth of the radiation therapy equipment market in hospitals are growing healthcare infrastructure and increased accessibility to healthcare services through wider adoption of health insurance.

Competitive Landscape

The radiation therapy devices market is highly competitive and consists of a few leading manufacturers of radiotherapy devices.

• In June 2020, Accuray announced the Cyberknife S7 system, which enables improved accuracy and real-time artificial intelligence powered motion tracking. This radiotherapy device is used to deliver treatments such as stereotactic radiosurgery, and stereotactic body radiation therapy. Cyberknife S7 system is a robotic, non-invasive radiation therapy device that can be used to treat malignant and benign tumours as well as neurologic problems across the body.

Bibliography

• World Health Organization. (2024). Global cancer observatory: Cancer today. International Agency for Research on Cancer.
• United States Food and Drug Administration. (2024). Radiological health: Medical imaging guidance. FDA Center for Devices and Radiological Health.
• National Institute for Health and Care Excellence. (2024). Radiotherapy in England: Service and technical specifications. NICE.
• European Commission. (2024). European cancer imaging initiative: Radiotherapy infrastructure assessment. Joint Research Centre.
• International Atomic Energy Agency. (2024). Setting up a radiotherapy programme: Clinical, medical physics, radiation protection and safety aspects. IAEA.
• Organisation for Economic Co-operation and Development. (2024). Cancer care: Assuring quality to improve survival. OECD Health Policy Studies.

This bibliography is provided for reader reference. The full FACT.MR report contains the complete reference list with primary research documentation.

This Report Addresses

• Market sizing and quantitative forecast metrics detailing capital equipment revenue projections for the Radiotherapy Devices market through 2036.
• Segmentation analysis mapping adoption velocity across external beam, brachytherapy, and proton therapy device categories by cancer application type.
• Regional intelligence comparing government cancer program-funded procurement in India and Brazil against technology-upgrade-driven demand in the USA and Germany.
• Regulatory compliance assessment analyzing EU MDR, FDA PMA, and international atomic energy authority requirements for radiotherapy device market access.
• Competitive landscape evaluation tracking software ecosystem integration, adaptive radiotherapy capability, and clinical outcome differentiation among major device manufacturers.
• Technology transition analysis identifying the clinical and economic drivers of conventional linac replacement by image-guided and stereotactic platform categories.
• Capital planning guidance defining procurement specification thresholds, service infrastructure requirements, and technology refresh cycle parameters for oncology center investment planning.
• Custom data delivery formats encompassing interactive dashboards, raw Excel datasets, and comprehensive PDF narrative reports.